Save Studies Locally
We can save your selected studies locally in your browser to enhance your experience. This data stays on your device and is not shared with us or third parties. You can clear this data at any time.
By allowing this, you consent to storing study selections locally on your device. Privacy Policy
How to NavigateConnectDistinguished InvestigatorsConferencesEducationRLT ComponentsSponsorsTrial Stats
FAPi Radioligand Open-Label, Phase 1 Study to Evaluate Safety, Tolerability and Dosimetry of [Lu-177]-PNT6555; A Dose Escalation Study for Treatment of Patients With Select Solid Tumors (FRONTIER)
Description:
This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
Sponsor:
Point BiopharmaGovernment Study Link:
NCT05432193 - Click here to see study onClinicalTrials.gov
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
United States 🇺🇸
Memorial Sloan Kettering Cancer Center
New York, New York 10065, United States
Canada 🇨🇦
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
CHUM - Centre hospitalier de l'Université de Montréal
H2X 3E4, Montréal, Quebec, Canada
Jewish General Hospital
Montréal, Quebec, Canada
